Drugs / Transdermal Contraceptive
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | XULANE | — | 2014-04-16 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04624867 | Nov 2020 → Jan 2022 | — | Noven Pharmaceuticals, Inc. | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02367833 | Jan 2015 → Dec 2017 | bone disorder | Penn State University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Transdermal Contraceptive | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02367833 ↗ |
| Known as | Xulane | “HP-1050 transdermal system (HP-1050) in comparison to XULANE patch” NCT04624867 ↗1“HP-1050 and Xulane will be administered simultaneously.” NCT04624867 ↗ |
| Route | Other | “Participants in the TDC group will apply a 20 cm2 patch (Xulane: 20µg/d EE,150µg/d norelgestromin) to the abdomen, upper arm or buttock.” NCT02367833 ↗ |